Liquid Biopsy

truXTRAC cfDNA™ Kits

designed to standardize circulating cell-free DNA extraction…
an active AFA-based, high-throughput, high-yield system

Circulating cell-free DNA (cfDNA) biomarker utilization in noninvasive prenatal testing (NIPT), cancer diagnosis, prognosis, and treatment monitoring is becoming increasingly prevalent, and has the potential of continuing to generate actionable clinical data when combined with next generation sequencing (NGS) technology. Unfortunately, the currently available methods for the extraction and purification of  cell-free DNA from whole blood are underdeveloped, low throughput, and specifically designed for use with fresh plasma or serum from K3EDTA-stabilized whole blood requiring rapid on-site processing since leukocyte lysis and genomic DNA contamination of K3EDTA-stabilized plasma begins shortly after collection and accelerates rapidly after 4 hours. Collectively, these barriers limit the number of samples that can practically be studied for the discovery and validation of actionable clinical mutations. Blood collection tubes such as the Streck Cell-Free DNA™ BCT* tubes, specially designed for ccfDNA stabilization, contain fixative releasing stabilizer agents that enable shipping and ambient storage of whole blood for up to 7 days without significant increase in genomic DNA contamination or ccfDNA degradation.

Contact us for the latest information on truXTRAC cfDNA.